Targeted Medical Pharma Profit Margin

The latest profit margin for TRGM is -57.86% as of December 2015. That compares with -54.76% in the prior-year period — down 5.6% year over year. That is below the sector sector average of 13.09%. Investors often review this figure alongside Targeted Medical Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, TRGM's profit margin moved from -54.76% to -57.86% — a 5.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Targeted Medical Pharma's valuation or profitability profile.

Against its sector companies, TRGM currently prints -57.86% for profit margin, while the sector average sits near 13.09%. That is roughly 542.0% below the sector mean. Large gaps often invite a closer look at Targeted Medical Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Targeted Medical Pharma converts resources into returns. At -57.86%, TRGM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -54.76% in the prior-year period — down 5.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TRGM's profit margin (-57.86%), review year-over-year change from -54.76%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.